## Abstract Nude mice bearing xenografts of the androgen‐independent human prostate‐cancer cell line PC‐3 were treated for 4 weeks with somatostatin analog RC‐160, bombesin/gastrin‐releasing peptide (GRP) antagonist (RC‐3095), or the combination of both peptides. In the first experiment, treatment
Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice
✍ Scribed by Pinski, Jacek; Halmos, Gabor; Schally, Andrew V.
- Book ID
- 122917385
- Publisher
- Elsevier Science
- Year
- 1993
- Tongue
- English
- Weight
- 657 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0304-3835
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Nude mice bearing xenografts of the gastrin‐responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with bombesin/gastrin‐releasing‐peptide(GRP) antagonist (RC‐3095), somatostatin analogues RC‐160 and SMS 201‐995, or the combination of RC‐3095 and RC‐160. Tumor
## Background: Hormones like bombesin (bn)/gastrin-releasing peptide (grp) and luteinizing hormone-releasing hormone (lh-rh) and growth factors such as epidermal growth factor (egf) might be involved in the relapse of prostate cancer under androgen ablation therapy. interference with receptors for